No surprises in Q1...work still in progress
17/05/18 -"Grifols delivered 7.4% constant currency revenue growth to €1.02bn, with an 11ppt forex headwind (primarily due to a depreciating USD) reducing the reported number to a decline of 3.6%. NB All ..."
Pages
60
Language
English
Published on
17/05/18
You may also be interested by these reports :
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...